Glioblastoma is the most common and lethal primary brain tumor which exhibits clinical, radiological and pathological heterogenity. Despite advances in standard therapy, including surgical resection, radiotherapy and chemotherapy, the prognosis for patients remains poor. In this book, the authors present topical research on the risk factors, diagnosis and treatment options for glioblastoma. Topics discussed include the therapeutic potential of scorpion toxins against glioblastoma; co-amplified oncogenes in glioblastoma; mesenchymal stem cells as a novel therapeutic delivery vehicle for glioblastoma; targeting fibroblast growth factor (FGF) signals and how to stop glial neoplastic brain development. (Imprint: Nova Biomedical)